205 related articles for article (PubMed ID: 19128229)
1. Endothelial effects of drugs designed to treat erectile dysfunction.
Aversa A; Caprio M; Rosano GM; Spera G
Curr Pharm Des; 2008; 14(35):3768-78. PubMed ID: 19128229
[TBL] [Abstract][Full Text] [Related]
2. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.
Sommer F; Schulze W
World J Urol; 2005 Dec; 23(6):385-92. PubMed ID: 16273418
[TBL] [Abstract][Full Text] [Related]
3. The erectile-endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention.
Watts GF; Chew KK; Stuckey BG
Nat Clin Pract Cardiovasc Med; 2007 May; 4(5):263-73. PubMed ID: 17457350
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction.
Aversa A; Bruzziches R; Pili M; Spera G
Curr Pharm Des; 2006; 12(27):3467-84. PubMed ID: 17017940
[TBL] [Abstract][Full Text] [Related]
5. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
Greco EA; Spera G; Aversa A
Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
[TBL] [Abstract][Full Text] [Related]
6. Testosterone therapy in erectile dysfunction and hypogonadism.
Shabsigh R
J Sex Med; 2005 Nov; 2(6):785-92. PubMed ID: 16422803
[TBL] [Abstract][Full Text] [Related]
7. Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statins.
Miner M; Billups KL
J Sex Med; 2008 May; 5(5):1066-1078. PubMed ID: 18331271
[TBL] [Abstract][Full Text] [Related]
8. Future options for combination therapy in the management of erectile dysfunction in older men.
Sommer F; Engelmann U
Drugs Aging; 2004; 21(9):555-64. PubMed ID: 15260511
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
Corbin JD; Francis SH; Webb DJ
Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
[TBL] [Abstract][Full Text] [Related]
10. The evolving role of testosterone in the treatment of erectile dysfunction.
Shabsigh R; Rajfer J; Aversa A; Traish AM; Yassin A; Kalinchenko SY; Buvat J
Int J Clin Pract; 2006 Sep; 60(9):1087-92. PubMed ID: 16939550
[TBL] [Abstract][Full Text] [Related]
11. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
Carson CC
BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
Axilrod AC
Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
[TBL] [Abstract][Full Text] [Related]
13. Endothelial antioxidant administration ameliorates the erectile response to PDE5 regardless of the extension of the atherosclerotic process.
Vicari E; La Vignera S; Condorelli R; Calogero AE
J Sex Med; 2010 Mar; 7(3):1247-53. PubMed ID: 19674252
[TBL] [Abstract][Full Text] [Related]
14. Sexual function in hypertensive patients receiving treatment.
Reffelmann T; Kloner RA
Vasc Health Risk Manag; 2006; 2(4):447-55. PubMed ID: 17323599
[TBL] [Abstract][Full Text] [Related]
15. PDE5 inhibitors for LUTS.
Mouli S; McVary KT
Prostate Cancer Prostatic Dis; 2009; 12(4):316-24. PubMed ID: 19687801
[TBL] [Abstract][Full Text] [Related]
16. Erectile dysfunction: pathophysiologic mechanisms pointing to underlying cardiovascular disease.
Ganz P
Am J Cardiol; 2005 Dec; 96(12B):8M-12M. PubMed ID: 16387559
[TBL] [Abstract][Full Text] [Related]
17. Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway.
Higashi Y
Int J Urol; 2017 Jun; 24(6):412-424. PubMed ID: 28332240
[TBL] [Abstract][Full Text] [Related]
18. Endothelial dysfunction and erectile dysfunction in the aging man.
Aversa A; Bruzziches R; Francomano D; Natali M; Gareri P; Spera G
Int J Urol; 2010 Jan; 17(1):38-47. PubMed ID: 20002226
[TBL] [Abstract][Full Text] [Related]
19. Drugs designed to improve endothelial function: effects on erectile dysfunction.
Shindel AW; Kishore S; Lue TF
Curr Pharm Des; 2008; 14(35):3758-67. PubMed ID: 19128228
[TBL] [Abstract][Full Text] [Related]
20. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model.
De Young L; Yu D; Freeman D; Brock GB
Int J Impot Res; 2003 Oct; 15(5):347-54. PubMed ID: 14562136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
